April 7, 2019
  • Marco Blei

Supplementary protection certificates: clarifications from the EU Court of Justice

In its judgment on Case C-443/17 of March 21, 2019, the European Court of Justice ruled on a significant patent issue following a preliminary ruling under Article 267 of the Treaty on the Functioning of the European Union (TFEU) from the High Court of Justice (England & Wales). Specifically, the issue concerned the possibility of considering a marketing authorization (MA) granted for a new formulation of an existing and authorized active ingredient, the first MA for the purposes of granting a supplementary protection certificate (SPC).


The United Kingdom’s Comptroller General of Patents rejected Abraxis Bioscience’s application for the granting of the SPC for the nab-paclitaxel medicinal product for treating cancer, marketed under the name “Abraxane”. In fact, the Comptroller declared that the medicinal product was missing one of the conditions necessary for granting the SPC as required by Article 3 (d) of Regulation (EC) no. 469/2009.

Specifically, according to the Comptroller, the MA granted for nab-paclitaxel could not be considered the product’s first MA subject to the SPC application. This decision is based on the fact that the old active ingredient, paclitaxel, contained in nab-paclitaxel within a new formulation with albumin, was already covered by the MA. Abraxis therefore challenged this decision before the EU High Court of Justice.

Conditions for granting an SPC 

According to the above-mentioned Regulation (EC) no. 469/2009 (Article 3), an SPC can be granted if the product, subject to the application, holds a currently valid MA (b) and if the MA is the first authorization for the medicinal product (d).

Given these conditions, the Court of Justice questioned whether the MA granted for the new formulation of an old active ingredient could be considered a new MA and therefore the first MA for that product. In order to solve this issue, the Court had to assess whether the new formulation of an existing active ingredient (including additional ingredients) represented a new and distinct product.

According to the Court of Justice the product corresponds with the active ingredient 

On this point, the Court confirmed a restrictive interpretation of the concept of “product”, including in its definition only the active ingredient. Ingredients that do not have any therapeutic effect (such as albumin in the present case) are therefore excluded since they act exclusively as vectors for the active ingredient, for example paclitaxel within the new formulation of the ingredient nab-paclitaxel. Consequently, nab-paclitaxel cannot be included within the definition of “product” according to the Regulation (EC) 469/2009 and therefore cannot constitute a distinct product from the old active ingredient.

These considerations give rise to the general principle according to which the new formulation of an old active ingredient does not constitute a new product, distinct from the previous product, when an active ingredient is combined with a substance lacking therapeutic effect and is therefore not considered within the concept of a ”product”.

The MA granted to the new formulation is not the first MA for the product 

Finally, the Court analyzed the possibility of considering the MA granted to the new formulation of an old active ingredient as the first authorization pursuant to Article 3 (d) of the referenced Regulation and it reached the conclusion that it was not possible to recognize the authorization as the first if the old active ingredient had already been covered by the MA.

This would, in fact, be contrary to the aim of the Regulation regarding SPCs, which aims to promote the protection of pharmaceutical research leading to the first placement on the market of an active ingredient or a combination of active ingredients, in a balanced approach to encourage investments in research for new pharmaceutical products and protect public health, as specified by the Court. Therefore, in such circumstances, the conditions for the granting of an SPC are not met.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

July 19, 2022
Guidelines for the implementation of the Electronic Health Record (EHR) to ensure dissemination, uniformity and accessibility of the EHR at national level now published in the Official Gazet...
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
April 5, 2022
Electronic prescriptions: the current modalities of transmission from doctors to patients and from patients to pharmacies are extended until 31st December 2022
March 24, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on appropriate surveillance of devices covered by certificates according to the MD Directives, under the transitional prov...
Search by...
Follow us on
Follow us on